A Special Ingredient (VtR) Containing Oligostilbenes Isolated fromVitis thunbergiiPrevents Bone Loss in Ovariectomized Mice:In VitroandIn VivoStudy
Open Access
- 11 April 2013
- journal article
- research article
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2013, 1-14
- https://doi.org/10.1155/2013/409421
Abstract
Vitis thunbergiiis used in Taiwan as a botanical supplement for inflammatory bone diseases. This study aims to examine its direct effect on bone metabolism. Three-month-old female mice were randomly divided into ovariectomized control (OVX), sham operated (SHAM), and ovariectomy treated with either 17β-estradiol or a special ingredient (VtR) fractionated from an ethanol extract ofV. thunbergiistarted two weeks after ovariectomy. VtR treatment for 8 weeks significantly ameliorated the deterioration of bone mineral density and reversed all the ovariectomy-induced changes in μ-CT parameters. The antiosteoporotic effect of VtR accompanied decrease in serum levels of C-terminal telopeptides of type I collagen (CTx), interleukin-7, and ration of RANKL/osteoprotegerin (OPG) but rise in osteocalcin concentration. Sparse calcified microarchitecture and less alkaline-phosphatase- (ALP-) positive cells were observed at the femur and vertebral sites in OVX mice while VtR remarkably restored such variation. HPLC analysis showed (+)-vitisin-A, (−)-vitisin-B, and ampelopsin C predominated in VtR. Both (−)-vitisin B and ampelopsin C increased ALP activity and bone nodule formation in cultured osteoblasts. Instead of stimulating osteoblastogenesis, (+)-vitisin A dramatically repressed osteoclasts differentiation and bone resorption. The results suggested VtR composed of diverse components to reciprocally drive osteoblastogenesis and interdict osteoclastogenesis may serve as a potential botanic drug for osteoporosis therapy.Keywords
Funding Information
- National Science Council (NSC101-2320-B-077-004-MY3, NRICM100-DMC-05, NRICM100-DBCM-02)
This publication has 40 references indexed in Scilit:
- Estrogen Modulates NFκB Signaling by Enhancing IκBα Levels and Blocking p65 Binding at the Promoters of Inflammatory Genes via Estrogen Receptor-βPLOS ONE, 2012
- The Anti-Inflammatory, Phytoestrogenic, and Antioxidative Role ofLabisia pumilain Prevention of Postmenopausal OsteoporosisAdvances in Pharmacological Sciences, 2012
- Antiosteoporotic Activity ofDioscorea alataL. cv. Phyto through Driving Mesenchymal Stem Cells Differentiation for Bone FormationEvidence-Based Complementary and Alternative Medicine, 2011
- 2‐Methoxystypandrone represses RANKL‐mediated osteoclastogenesis by down‐regulating formation of TRAF6–TAK1 signalling complexesBritish Journal of Pharmacology, 2010
- Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?Wiener Medizinische Wochenschrift, 2010
- Oligomerized grape seed polyphenols attenuate inflammatory changes due to antioxidative properties in coculture of adipocytes and macrophagesThe Journal of Nutritional Biochemistry, 2010
- Oligostilbenes from the Roots ofVitis thunbergiiPlanta Medica, 2009
- Circulating osteoprotegerin and receptor activator of NF-κB ligand system in patients with β-thalassemia majorJournal of Bone and Mineral Metabolism, 2006
- Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitroJournal of Bone and Mineral Metabolism, 2006
- Molecular analysis of RANKL‐independent cell fusion of osteoclast‐like cells induced by TNF‐α, lipopolysaccharide, or peptidoglycanJournal of Cellular Biochemistry, 2006